Core Viewpoint - The article discusses the official launch of the Hainan Free Trade Port's full island closure on December 18, which is expected to create a special customs regulatory area and implement a policy of "one line open, two lines controlled, and free within the island" [5][6]. Group 1: Policy Implications - The "one line open" policy allows for more freedom and convenience for people, capital, goods, and data from foreign countries and regions to enter Hainan [6]. - The "two lines controlled" policy means that special policies applicable only within Hainan will be managed by mainland policies when elements enter the mainland [6]. - The closure is anticipated to optimize the development environment for the private economy and stimulate investment activity, providing clear development opportunities for multiple industries [6]. Group 2: Beneficiary Industries - Industries such as import-export trade, international shipping, and logistics will directly benefit from customs facilitation and tax incentives [7]. - The tourism, hotel, exhibition, cultural entertainment, and healthcare sectors are expected to expand due to visa-free and tax-free policies, attracting more international visitors [7]. - High-end manufacturing and technology sectors, including biomedicine and digital economy, will benefit from zero tariffs and low tax rates, reducing R&D costs and attracting businesses [7]. Group 3: Investment Opportunities - The closure is seen as a significant opportunity for the trade sector and will help Hainan accelerate its development as an international tourism consumption center [7]. - Stakeholders in the tourism industry, including scenic spots, hotels, and travel retailers, are expected to benefit in the long term [7]. - Areas such as duty-free shopping, cross-border finance, and international shipping are projected to present investment opportunities post-closure [7].

Core Viewpoint - The establishment of the Hainan Free Trade Port and its full closure starting December 18 will create significant opportunities for various industries, particularly in manufacturing and new materials, by implementing favorable tax policies such as "zero tariffs" for certain imported goods [2][3]. Group 1: Hainan Free Trade Port Overview - The full closure of Hainan Island will create a special customs supervision area, allowing for a series of liberalized policies that facilitate trade with foreign countries while managing imports from the mainland [2]. - The "zero tariff" policy will apply to certain goods imported into Hainan, significantly reducing costs for manufacturing enterprises that require large amounts of equipment and raw materials [2][3]. Group 2: Tax Policies and Economic Impact - The processing value-added exemption from import duties applies to goods produced by encouraged industries that either do not contain imported materials or have over 30% value added from processing in Hainan [3]. - The total value of goods sold domestically under the processing value-added exemption has exceeded 10 billion yuan, with over 800 million yuan in import duties exempted, enhancing the competitiveness of Hainan's manufacturing sector [3]. Group 3: Expansion of Zero Tariff Goods - The range of goods eligible for the "zero tariff" policy has expanded significantly from over 1,900 items to more than 6,600 items, increasing the proportion of zero-tariff goods from 21% to 74% of all tariff items [3]. Group 4: Benefiting Industries - The petrochemical new materials industry in Hainan is highlighted as a key beneficiary, with a historical high output value projected for 2024 and consistent double-digit growth over the past four years [4]. - The Hainan government is promoting a complete industrial chain from upstream exploration and development to downstream new materials production, focusing on olefins, aromatics, and natural gas [4]. Group 5: Key Enterprises in Hainan - The top enterprises in Hainan's manufacturing sector for 2024 include China Petroleum & Chemical Corporation (Sinopec) Hainan Refining & Chemical Co., with a projected revenue of 7.89 billion yuan, followed by Hainan Natural Rubber Industry Group Co. and Hainan Yisheng Petrochemical Co. [6][7].

第四届董事会2025年 第三次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：605199 证券简称：ST葫芦娃 公告编号：2025-089 海南葫芦娃药业集团股份有限公司 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第四届董事会2025年第三次临时会议的召 开符合《公司法》《公司章程》和《董事会议事规则》的有关规定，会议合法有效。 （二）会议通知于2025年12月11日以通讯方式发出。 （三）会议于2025年12月15日在海南省海口市秀英区安读一路30号公司会议室以现场结合通讯方式召 开。 （四）公司董事会会议应出席董事7人，实际出席董事7人（其中以通讯表决方式出席会议的董事2 人）。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体高级管理人员列席会议。 二、董事会会议审议情况 （一）审议通过了《关于聘任2025年度会计师事务所的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫芦娃药业集团股份有 限公司关于聘任 ...

● 原聘任的会计师事务所名称：立信会计师事务所（特殊普通合伙）（以下简 称"立信"） ● 变更会计师事务所的简要原因及前任会计师的异议情况：鉴于原会计师事 务所立信的聘期已满，根据《国有企业、上市公司选聘会计师事务所管理办法》与 公司《会计师事务所选聘制度》等相关规定，综合考虑公司实际经营需要和对审计 服务的需求，公司拟聘任政旦志远为公司 2025 年度财务审计和内部控制审计机构。 公司已就会计师事务所变更事宜与原聘任的立信进行了充分沟通，立信对本次变更 事宜无异议。 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-090 海南葫芦娃药业集团股份有限公司 关于聘任 2025 年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 拟聘任的会计师事务所名称：政旦志远（深圳）会计师事务所（特殊普通 合伙）（以下简称"政旦志远"） ● 本次变更事项尚需提交股东会审议 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）机构名称：政旦志远（深圳）会计师事务所（特 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-091 (一) 股东会类型和届次 2025年第三次临时股东会 召开的日期时间：2025 年 12 月 31 日 14 点 30 分 召开地点：海南省海口市秀英区安读一路 30 号公司会议室 (五) 网络投票的系统、起止日期和投票时间。 海南葫芦娃药业集团股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 股东会召开日期：2025年12月31日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 31 日 至2025 年 12 月 31 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日 ...

每经AI快讯，ST葫芦娃（SH 605199，收盘价：8.62元）12月15日晚间发布公告称，公司第四届2025年 第三次董事会临时会议于2025年12月15日在海南省海口市秀英区安读一路30号公司会议室以现场结合通 讯方式召开。会议审议了《关于聘任2025年度会计师事务所的议案》等文件。 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ （记者 王晓波） 2024年1至12月份，ST葫芦娃的营业收入构成为：医药制造业占比100.0%。 截至发稿，ST葫芦娃市值为34亿元。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-089 海南葫芦娃药业集团股份有限公司 第四届董事会 2025 年第三次临时会议决议公告 表决结果：同意 7 票，弃权 0 票，反对 0 票。 本议案已经公司董事会审计委员会审议通过并同意提交公司董事会审议。 （二）审议通过了《关于提请召开 2025 年第三次临时股东大会的议案》 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第四届董事会 2025 年第三次临时会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关 规定，会议合法有效。 （二）会议通知于 2025 年 12 月 11 日以通讯方式发出。 （三）会议于 2025 年 12 月 15 日在海南省海口市秀英区安读一路 30 号公司会 议室以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决 方式出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主 ...

Group 1 - The flu activity in China is on the rise, with a peak expected between mid-December and early January, leading to increased demand for antiviral and symptomatic treatment drugs, especially among children [1] - Bank securities report indicates that antiviral drugs are the main treatment method, with good expected efficacy; various traditional Chinese medicines and antipyretics are also available to alleviate symptoms during the illness [1] - Data from Meituan shows that since November, the overall order volume for specific flu medications has increased by over 100%, with orders for Oseltamivir granules rising by over 85% and for Baloxavir increasing by over 110% [1] Group 2 - Hainan Huhuwawa Pharmaceutical Group's Oseltamivir products have performed well, with capsules approved for production and stable market supply for the prevention and treatment of influenza A and B [3] - The company has developed a dry suspension that received drug registration certification in September, addressing dosage challenges for young children aged two and above [3] - The core product, Pediatric Lung Heat Cough and Asthma Granules, has been included in national treatment guidelines and health insurance directories, enhancing its market presence [3] Group 3 - Huhuwawa Pharmaceutical emphasizes research and innovation as a core driver for development, continuously enhancing R&D efforts in the pediatric medication sector [4] - The company has increased investment in R&D for pediatric drugs, with ongoing projects targeting infectious diseases, functional dyspepsia, allergic diseases, and adenoid hypertrophy [4]

Core Viewpoint - ST HULUWAWA (605199) announced that its controlling shareholder, Hainan Huluwawa Investment Development Co., Ltd., has had 23.9 million shares judicially frozen, representing 14.3% of its holdings and 5.97% of the company's total share capital [1] Group 1 - The freezing period for the shares is from December 5, 2025, to December 3, 2028 [1] - The shares were pledged to Shandong International Trust in October 2024 for a two-year period [1] - The freezing was initiated by Shandong International Trust due to triggering early redemption clauses, leading to a court application for the freeze [1] Group 2 - Hainan Huluwawa Investment is currently in communication with various parties to resolve the issue promptly [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-088 海南葫芦娃药业集团股份有限公司 关于控股股东部分股份被司法冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东海南葫芦娃投资发展有限公司（以下简称"葫芦娃投资"）持 有公司 167,079,000 股，占公司总股本 41.76%，葫芦娃投资持有公司的部分股份被 司法冻结 23,900,000 股，占其持股 14.30%，占公司总股本 5.97%。冻结期限由 2025 年 12 月 5 日至 2028 年 12 月 3 日。 （二）股东股份累计被冻结情况 截至本公告披露日，公司控股股东及其一致行动人累计被冻结股份情况如下： 一、股份被冻结情况 1 （一）本次股份被冻结基本情况 股东名称 冻结股 份数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 冻结/标 记股份是 否为限售 股 冻结/ 标记 起始日 冻结/ 标记 到期日 冻结 申请人 冻结 原因 海南葫芦 娃投资发 展有限公 23,900 ,0 ...